Background: COVID-19 infection has been a major cause of hospitalization and mortality in the United States. Patients with liver cirrhosis may be especially vulnerable to severe outcomes of COVID-19 infection because of immune dysfunction, systemic inflammation, portal hypertension, and reduced physiologic reserve. These factors can increase the risk of severe infection, multiorgan complications, and poor inpatient outcomes. Using the 2020-2022 United States National Inpatient Sample, this study evaluates the effect of cirrhosis among adults hospitalized with COVID-19. Methods: We performed a retrospective cohort study using the National Inpatient Sample (NIS) database. Adult hospitalizations with COVID-19 from 2020 to 2022 were included and stratified according to the presence or absence of cirrhosis. Using multivariable logistic regression analyses, we evaluated in-hospital mortality as the primary outcome. Secondary outcomes included need for mechanical ventilation, septic shock, ARDS, ECMO utilization, acute kidney injury, renal replacement therapy, length of stay, and hospital charges. Results: A total of 5,934,565 hospitalized COVID-19 patients were included, of which 115,170 had concomitant cirrhosis. COVID-19 patients with cirrhosis had a higher in-hospital mortality than those without cirrhosis (16.8% vs. 11.3%; aOR 1.28; 95% CI 1.22-1.32). Patients with liver cirrhosis were also associated with higher odds of invasive mechanical ventilation, vasopressor use and septic shock. Conclusions: Cirrhosis was independently associated with increased in-hospital mortality and complications including need for invasive mechanical ventilation and septic shock in adults hospitalized with COVID-19. Although mortality associated with these patients have declined over time, they represent a high risk group that requires close monitoring.
9 December 2025 in Antimicrobial Stewardship & Healthcare Epidemiology
Intra-abdominal infections (IAIs) are common in both the inpatient and outpatient setting but are not often a target for antimicrobial stewardship programs (ASP). However, IAIs provide ASPs an opportunity to translate evidence into practice while also addressing empiric broad-spectrum antibiotic use and establishing relationships with surgical stakeholders. In this review, we analyze five areas of emerging evidence within this heterogeneous field that merit close attention from ASPs, including spontaneous bacterial peritonitis prophylaxis, antibiotic management of appendicitis and biliary tract infections, and optimal amoxicillin-clavulanate and metronidazole dosing.
Background: COVID-19 infection has been a major cause of hospitalization and mortality in the United States. Patients with liver cirrhosis may be especially vulnerable to severe outcomes of COVID-19 infection because of immune dysfunction, systemic inflammation, portal hypertension, and reduced physiological reserve. These factors can increase the risk of severe infection, multiorgan complications, and poor inpatient outcomes. Using the 2020–2022 United States National Inpatient Sample, this study evaluates the effect of cirrhosis among adults hospitalized with COVID-19. Methods: We performed a retrospective cohort study using the National Inpatient Sample (NIS) database. Adult hospitalizations with COVID-19 from 2020 to 2022 were included and stratified according to the presence or absence of cirrhosis. Using multivariable logistic regression analyses, we evaluated in-hospital mortality as the primary outcome. Secondary outcomes included the need for mechanical ventilation, septic shock, ARDS, ECMO utilization, acute kidney injury, renal replacement therapy, length of stay, and hospital charges. Results: A total of 5,934,565 hospitalized COVID-19 patients were included, of which 115,170 had concomitant cirrhosis. COVID-19 patients with cirrhosis had a higher in-hospital mortality than those without cirrhosis (16.8% vs. 11.3%; aOR 1.28; 95% CI 1.22–1.32). Patients with liver cirrhosis were also associated with higher odds of invasive mechanical ventilation, vasopressor use, and septic shock. Conclusions: Cirrhosis was independently associated with increased in-hospital mortality and complications including the need for invasive mechanical ventilation and septic shock in adults hospitalized with COVID-19. Although mortality associated with these patients has declined over time, they represent a high-risk group that requires close monitoring.
22 September 2025 in Antimicrobial Stewardship & Healthcare Epidemiology
Objective: Discharge is a pivotal transition of care moment; however, discharge antibiotic stewardship efforts have historically been limited. Our institution has a mandatory indication field for inpatient antibiotic orders. Using the last-ordered inpatient antibiotic indication (“Last Inpatient Indication”), we assessed the utility of this field compared to the ICD-10 in inferring clinician intent for discharge antibiotics, to forgo the need for manual chart review to assess antibiotic appropriateness. Methods: We extracted electronic medical record data on adult inpatient encounters in 2023 with ≤2 discharge antibiotics. We reviewed a random subset of 300 encounters to determine if the ICD-10 or Last Inpatient Indication had higher agreement with clinician intent for discharge antibiotics, as determined by chart notes. To facilitate comparison, we created a dictionary classifying ICD-10 indications. Results: We included 3,414 encounters. The most common discharge antibiotics were amoxicillin/clavulanate (24%) and ciprofloxacin (15%). The most common ICD-10s were non-infectious (48%) and sepsis (18%). In the subset of chart-reviewed encounters, the Last Inpatient Indication agreed with the documented clinician intent for discharge antibiotic more often than the ICD-10 (84% vs 28%). Applying institutional guidelines, we were able to use the Last Inpatient Indication to assess appropriate duration and choice of discharge antibiotics for select infections. Conclusions: The Last Inpatient Indication outperformed ICD-10s in inferring clinician intent for discharge antibiotics and can be used to efficiently assess antibiotic appropriateness without need for manual chart review. Usefulness of ICD-10s was limited by high percentage of non-infectious and sepsis codes.
17 March 2026 in Infectious Diseases in Clinical Practice
Background: Leukocytosis as a marker of inflammation is commonly seen after left ventricular assist device (LVAD) placement. Differentiating reactive postoperative leukocytosis from infection can drive antimicrobial stewardship initiatives. Methods: We conducted a retrospective chart review of adults who underwent durable LVAD implantation between 2017 and 2019 at a tertiary care hospital. We described the white blood cell (WBC) count trends postoperatively after LVAD placement. Secondary outcomes included comparing the WBC trends between patients with and without bacteremia or clinical evidence of infection requiring antimicrobial therapy. Results: We included 115 LVAD patients with a median age of 61 years. We noted a peak in median WBC count to 14.3 (×10 3 /μL) (interquartile range: 11.3, 17.6) on day 2 postoperatively and another, slightly lower peak of 14.0 between days 10 and 12. After day 12, the median WBC count declined gradually to a normal range. There were 8 (6.9%) LVAD patients with clinical or microbiological evidence of infection; postoperative WBC trends were similar when these patients were excluded. Conclusions: Postoperative leukocytosis is common after cardiopulmonary bypass, especially in LVAD patients. This expected post-LVAD leukocytosis should not prompt antimicrobial therapy without other signs of infection.